title: Probiotics and prebiotics to combat enteric infections and HIV in the developing world: a consensus report.
abstract: Infectious disease in the developing world continues to represent one of the greatest challenges facing humanity. Every year over a million children suffer and die from the sequela of enteric infections, while in 2008 it is estimated almost 2.7 million (UNAIDS 2009 update) adults and children became infected with human immunodeficiency virus (HIV). While oral rehydration therapy for diarrhea, and antiretrovirals (ARV) for HIV are critical, there is a place for adjunctive therapies to improve quality of life. The importance of the human microbiota in retaining health is now recognized, as is the concept of replenishing beneficial microbes through probiotic treatments. Studies have shown that probiotics can reduce the duration of diarrhea, improve gut barrier function, help prevent bacterial vaginosis (BV), and enhance immunity even in HIV-infected subjects. However, many issues remain before the extent of probiotic benefits can be verified, and their application to the developing world realised. This consensus report outlines the potential probiotic, and to a lesser extent prebiotic, applications in resource disadvantages settings, and recommends steps that could bring tangible relief to millions of people. The challenges to both efficacy and effectiveness studies in these settings include a lack of infrastructure and funding for scientists, students and research projects in developing countries; making available clinically proven probiotic and prebiotic products at affordable prices; and undertaking appropriately designed clinical trials. We present a roadmap on how efficacy studies may be conducted in a resource disadvantages setting among persons with chronic diarrhea and HIV. These examples and the translation of efficacy into effectiveness are described.
authors.affiliation: Canadian Research and Development Centre for Probiotics, Human Microbiology and Probiotics, Lawson Health Research Institute, Canada.
authors.forename: Marc
authors.initials: M
authors.lastname: Monachese
authors.forename: Susanna
authors.initials: S
authors.lastname: Cunningham-Rundles
authors.forename: Maria Alejandra
authors.initials: MA
authors.lastname: Diaz
authors.forename: Richard
authors.initials: R
authors.lastname: Guerrant
authors.forename: Ruben
authors.initials: R
authors.lastname: Hummelen
authors.forename: Rober
authors.initials: R
authors.lastname: Kemperman
authors.forename: Marko
authors.initials: M
authors.lastname: Kerac
authors.forename: Remco
authors.initials: R
authors.lastname: Kort
authors.forename: Dan
authors.initials: D
authors.lastname: Merenstein
authors.forename: Pinaki
authors.initials: P
authors.lastname: Panigrahi
authors.forename: Balakrishnan
authors.initials: B
authors.lastname: Ramakrishna
authors.forename: Nasia
authors.initials: N
authors.lastname: Safdar
authors.forename: Andi
authors.initials: A
authors.lastname: Shane
authors.forename: Livia
authors.initials: L
authors.lastname: Trois
authors.forename: Gregor
authors.initials: G
authors.lastname: Reid
mesh_terms: D002675:Child, Preschool; D003906:Developing Countries / Q000706:statistics & numerical data; D003967:Diarrhea / Q000188:drug therapy* / Q000276:immunology; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007223:Infant; D008297:Male; D056692:Prebiotics / Q000706:statistics & numerical data*; D019936:Probiotics / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic
chemical_list: D056692:Prebiotics